MedTrace Logo

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

NCT00462488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).

Conditions

  • Urinary Bladder Cancer
  • Bladder Cancer
  • Bladder Neoplasms
  • Bladder Tumors

Interventions

DRUG

Vicinium

Intravesical administration of Vicinium

Sponsors & Collaborators

  • Sesen Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Wendy Chapman · Sesen Bio, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00462488 on ClinicalTrials.gov